Mactier Mhairi, Mansell James, Arthur Laura, Doughty Julie, Romics Laszlo
Wolfson Wohl Cancer Research Centre, College of Medicine and Veterinary Science, University of Glasgow, Glasgow, UK.
General Surgery Department, Golden Jubilee National Hospital, Clydebank, UK.
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zraf002.
Recent evidence suggests a survival advantage after breast-conserving surgery compared with mastectomy. Previous studies have compared survival outcomes after standard breast-conserving surgery, but no studies have compared survival outcomes after oncoplastic breast-conserving surgery. The aim of this study was to compare survival outcomes after breast-conserving surgery + radiotherapy (and an oncoplastic breast-conserving surgery + radiotherapy subgroup) with those after mastectomy ± radiotherapy.
Patients diagnosed with primary invasive breast cancer between 1 January 2010 and 31 December 2019 were identified from a prospectively maintained National Cancer Registry. Overall survival and breast cancer-specific survival outcomes were analysed using Kaplan-Meier analysis and Cox regression analysis adjusting for patient demographics, tumour characteristics, and treatment adjuncts.
A total of 14 182 patients were eligible (8537 patients underwent standard breast-conserving surgery + radiotherapy, 360 patients underwent oncoplastic breast-conserving surgery + radiotherapy, 2953 patients underwent mastectomy + radiotherapy, and 2332 patients underwent mastectomy - radiotherapy). The median follow-up was 7.27 (range 0.2-13.6) years. Superior 10-year survival was observed after breast-conserving surgery + radiotherapy (overall survival: 81.2%; breast cancer-specific survival: 93.3%) compared with mastectomy + radiotherapy (overall survival: 63.4%; breast cancer-specific survival: 75.9%) and mastectomy - radiotherapy (overall survival: 63.1%; breast cancer-specific survival: 87.5%). Ten-year overall survival and breast cancer-specific survival after oncoplastic breast-conserving surgery + radiotherapy were 86.1% and 90.2% respectively. After adjusted analysis, breast-conserving surgery + radiotherapy was associated with superior survival outcomes compared with mastectomy + radiotherapy (overall survival: HR 1.34 (95% c.i. 1.20 to 1.51); breast cancer-specific survival: HR 1.62 (95% c.i. 1.38 to 1.90)) and mastectomy - radiotherapy (overall survival: HR 1.57 (95% c.i. 1.41 to 1.75); breast cancer-specific survival: HR 1.70 (95% c.i. 1.41 to 2.05)). Similar survival outcomes were observed amongst patients treated with oncoplastic breast-conserving surgery + radiotherapy compared with mastectomy + radiotherapy (overall survival: HR 1.72 (95% c.i. 1.62 to 2.55); breast cancer-specific survival: HR 1.74 (95% c.i. 1.06 to 2.86)) and mastectomy - radiotherapy (overall survival: HR 2.21 (95% c.i. 1.49 to 3.27); breast cancer-specific survival: HR 1.89 (95% c.i. 1.13 to 3.14)).
Breast-conserving surgery + radiotherapy and oncoplastic breast-conserving surgery + radiotherapy are associated with superior overall survival and breast cancer-specific survival compared with mastectomy ± radiotherapy. The findings should inform discussion of surgical treatment options for patients with breast cancer.
近期证据表明,保乳手术相比乳房切除术具有生存优势。以往研究比较了标准保乳手术后的生存结果,但尚无研究比较肿瘤整形保乳手术后的生存结果。本研究的目的是比较保乳手术 + 放疗(以及肿瘤整形保乳手术 + 放疗亚组)与乳房切除术 ± 放疗后的生存结果。
从前瞻性维护的国家癌症登记处识别出2010年1月1日至2019年12月31日期间诊断为原发性浸润性乳腺癌的患者。使用Kaplan-Meier分析和Cox回归分析对总生存和乳腺癌特异性生存结果进行分析,并对患者人口统计学、肿瘤特征和治疗辅助因素进行校正。
共有14182例患者符合条件(8537例患者接受标准保乳手术 + 放疗,360例患者接受肿瘤整形保乳手术 + 放疗,2953例患者接受乳房切除术 + 放疗,2332例患者接受乳房切除术 - 放疗)。中位随访时间为7.27(范围0.2 - 13.6)年。与乳房切除术 + 放疗(总生存:63.4%;乳腺癌特异性生存:75.9%)和乳房切除术 - 放疗(总生存:63.1%;乳腺癌特异性生存:87.5%)相比,保乳手术 + 放疗后的10年生存率更高(总生存:81.2%;乳腺癌特异性生存:93.3%)。肿瘤整形保乳手术 + 放疗后的10年总生存和乳腺癌特异性生存分别为86.1%和90.2%。校正分析后,与乳房切除术 + 放疗(总生存:HR 1.34(95%置信区间1.20至1.51);乳腺癌特异性生存:HR 1.62(95%置信区间1.38至1.90))和乳房切除术 - 放疗(总生存:HR 1.57(95%置信区间1.41至1.75);乳腺癌特异性生存:HR 1.70(95%置信区间1.41至2.05))相比,保乳手术 + 放疗与更好的生存结果相关。与乳房切除术 + 放疗(总生存:HR 1.72(95%置信区间1.62至2.55);乳腺癌特异性生存:HR 1.74(95%置信区间1.06至2.86))和乳房切除术 - 放疗(总生存:HR 2.21(95%置信区间1.49至3.27);乳腺癌特异性生存:HR 1.89(95%置信区间1.13至3.14))相比,肿瘤整形保乳手术 + 放疗的患者观察到相似的生存结果。
与乳房切除术 ± 放疗相比,保乳手术 + 放疗和肿瘤整形保乳手术 + 放疗与更好的总生存和乳腺癌特异性生存相关。这些发现应为乳腺癌患者手术治疗方案的讨论提供参考。